Abstract:Jieyang Yu, 1, 2 Yanan Zhang, 1 Lijia Cai, 1 Qingqing Sun, 1 Wanru Li, 1 Junfang Zhou, 1 Jianmin Liang, 2 Zan Wang 1 1 Sleep Centre, Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China; 2 Department of Pediatric Neurology, The First Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China Correspondence: Jianmin Liang, Department of Pediatric Neurology, The First Hospital of Jilin University, Changchun, Jilin Province, 130021, People's Republic of China, Email Zan Wang, Sleep Centre, Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin Province, 130021, People's Republic of China, Email ; Purpose: This study aimed to evaluate nocturnal sleep structure and anxiety, depression, and fatigue in patients with narcolepsy type 1 (NT1). Methods: Thirty NT1 patients and thirty-five healthy controls were enrolled and evaluated using the Epworth sleepiness scale (ESS), Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, Fatigue Severity Scale (FSS), polysomnography, multiple sleep latency test, and brain function state monitoring. Statistical analyses were performed using SPSS Statistics for Windows, version 23.0. Benjamini-Hochberg correction was performed to control the false discovery rate. Results: Apart from typical clinical manifestations, patients with NT1 are prone to comorbidities such as nocturnal sleep disorders, anxiety, depression, and fatigue. Compared with the control group, patients with NT1 exhibited abnormal sleep structure, including increased total sleep time ( P adj =0.007), decreased sleep efficiency ( P adj =0.002), shortening of sleep onset latency ( P adj < 0.001), elevated wake after sleep onset ( P adj =0.002), increased N1% ( P adj =0.006), and reduced N2%, N3%, and REM% ( P adj =0.007, P adj < 0.001, P adj =0.013). Thirty-seven percent of patients had moderate to severe obstructive sleep apnea-hypopnea syndrome. And sixty percent of patients were complicated with REM sleep without atonia. Patients with NT1 displayed increased anxiety propensity ( P adj < 0.001), and increased brain fatigue ( P adj =0.020) in brain function state monitoring. FSS scores were positively correlated with brain fatigue ( P adj < 0.001) and mean sleep latency was inversely correlated with FSS scores and brain fatigue ( P adj =0.013, P adj =0.029). Additionally, ESS scores and brain fatigue decreased after 3 months of therapy ( P =0.012, P =0.030). Conclusion: NT1 patients had abnormal nocturnal sleep structures, who showed increased anxiety, depression, and fatigue. Excessive daytime sleepiness and fatigue improved after 3 months of treatment with methylphenidate hydrochloride prolonged-release tablets in combination with venlafaxine. Keywords: narcolepsy, sleep structure, excessive daytime sleepiness, anxiety, depression, fatigue Narcolepsy is a rare lifelong sleep disorder characterized by excessive daytime sleepiness (EDS), cataplexy, sleep hallucinations, and sleep paralysis. The prevalence of narcolepsy is estimated to be between 0.00023% and 0.05% in various nations worldwide, with a higher prevalence observed in males. 1–4 It can occur at any age, with two peaks at ages 15 and 35. 1,4,5 Early onset narcolepsy, with an onset age before 15 years, accounts for 86% of all cases. 6 EDS is frequently the initial symptom in younger individuals, whereas cataplexy is more common in individuals over 60 years of age. 7 In addition, patients with narcolepsy have disrupted sleep structure and are prone to comorbidities with other sleep disorders. 8 Based on the presence of cataplexy or low or absent hypocretin-1 (Hcrt-1) levels in cerebrospinal fluid (CSF), the International Classification of Sleep Disorders, Third Edition (ICSD-3) classifies narcolepsy into Narcolepsy Type 1 (NT1) and Narcolepsy Type 2. Selective loss of hypocretin (Hcrt) neurons in the lateral hypothalamus is the characteristic pathological change in NT1. 9 Current evidence favors NT1 is an autoimmune condition mediated by interactions between CD4+ T cells and CD8+ T cells in genetically susceptible individuals carrying HLA-DQB1* 06:02 or HLA-DQB1* 03:01 alleles, which affects Hcrt neurons and interferes with sleep-wakefulness neural circuits. 2,10,11 A study of 9312 narcolepsy patients conducted by Ruoff et -Abstract Truncated-

Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?

Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

Recent insights into the pathophysiology of narcolepsy type 1

[Value of Cerebral Spinal Fluid Measurement of Hypocretin-1 in the Diagnosis of Chinese Patients with Narcolepsy].

0648 NARCOLEPSY SPECTRUM DISORDER IN 378 PARENTS OF PATIENTS WITH TYPE 1 NARCOLEPSY-CATAPLEXY

Alterations in the DTI-ALPS index and choroid plexus volume are associated with clinical symptoms in participants with narcolepsy type 1

The Changed Nocturnal Sleep Structure and Higher Anxiety, Depression, and Fatigue in Patients with Narcolepsy Type 1

Neuropsychological Alterations in Narcolepsy with Cataplexy and the Expression of Cognitive Deficits

NocturnalRapidEyeMovementSleepLatencyforIdentifying PatientsWithNarcolepsy/HypocretinDeficiency

Exploring the emotional and behavioural profile in paediatric narcolepsy type 1: A case-control study

Executive function performance in children and adolescent patients with narcolepsy type 1

Narcolepsy and Other Central Hypersomnias

High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2

Advances in narcolepsy

0599 Sleep Stage Transition Patterns Among Youth with CNS Disorders of Hypersomnolence

Serum N-Glycan Profiling of Patients with Narcolepsy Type 1 Using LC-MS/MS

Nocturnal Rapid Eye Movement Sleep Latency for Identifying Patients with Narcolepsy/Hypocretin Deficiency

Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis

Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in Narcolepsy type 2

Altered Sleep Stage Transitions of REM Sleep: A Novel and Stable Biomarker of Narcolepsy

Lipocalin-type prostaglandin D synthase levels increase in patients with narcolepsy and idiopathic hypersomnia